Excellent presentation by @MikeFoley89 at #TCT2024 on physiology stratified analysis of ORBITA-2. FFR and iFR clearly predict the placebo controlled benefit of PCI. Especially in those with typical symptoms. @rallamee@SukhNijjer@RicardoPetraco
Cardiology research is “on FiRE” in Portsmouth today. 2 wonderful cases using in depth coronary physiology and imaging as part of the Orbita Fire study. As always super support from the wonderful @fiyyazAJ, Chris and team.
🎉New NovPods!
This time @DoreEoin and Dr Duncan Kemp are joined by @RosannaEGrimes to navigate us through the world of obstetric anaesthesia.
Episode 1: A typical day on labour ward
Episode 2: Maternal physiology with @LaylaGuscoth
🎧 https://t.co/PbX22JKIHN
@OAAinfo
Should PCI be an option for first line management of stable angina symptoms?
Point and counterpoint in @CircOutcomes with final word from @bnallamo and @TCTMD
https://t.co/501Y7HHgKB
@rallamee
🙏🏻 @rallamee for coming to @UHD_NHS today to proctor our first 4 coronary sinus reducer cases @ShockwaveIVL
Great to get clinical program started after #ORBITACOSMIC@TheLancet & important we can now offer symptom relief for angina beyond PCI/CABG/OMT 👏🏻👏🏻 great job whole team
Just in case you thought the ORBITA team had gone on summer vacation… The first ORBITA-MOON case was completed yesterday. Another n-of-1 trial that might have some interesting results. Well done @ShaynaChotai on achieving the first of many big milestones during your PhD!
Proud of my friend @rajkumar_chris presenting the game changing ORBITA-STAR trial on the main stage at #EuroPCR2024. EuroPCR’s got talent winner - well deserved against excellent competition. @rallamee@mshunshin
Proud to be a co-author with @rallamee@mshunshin on a 100% Bayesian clinical trial paper that also uses our latest longitudinal ordinal modeling approach, helped by the #rstats rmsb package: https://t.co/lLPCAPbPRC How can cardiologist Matthew Shun-Shin master all this?
I’m delighted to see our paper highlighted by TCT MD. Our belief in a therapy is associated with how intuitive it seems. This may subconsciously influence the threshold we set for randomised data. We should keep this in mind as we appraise procedures, new and old. @rallamee
🚨 🚨
Please share with starting Novices for a warm welcome into the world of anaesthesia. The links have some feedback on them,if you’ve had a listen please leave your thoughts. What would you want to be in season 2? @drjonchambers1@hasyourregtried@doctorhelgi@LaylaGuscoth
Have you already metabolized the outcomes of ORBITA 2? Next stop in the ORBITA program is called ORBITA-COSMIC. The coronary sinus Reducer (CSR) is an hourglass-shaped device which creates an artificial stenosis in the coronary sinus. The ORBITA-COSMIC trial is a randomized, placebo-controlled, double-blind trial investigating the efficacy of the CSR on quantified myocardial perfusion and stable angina. Here is the study rationale and design paper. https://t.co/wrshmjsGdh
There is an unsung hero in the ORBITA family and we don’t do forgotten heroes. @mshunshin is the cleverest man I know and responsible for all the statistics and beautiful figures in ORBITA-2 (with a little help from my RAL chart). Give this man a round of applause!